Literature DB >> 31388668

To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program.

Andrew D Wiese1, Carlos G Grijalva1,2.   

Abstract

Entities:  

Year:  2020        PMID： 31388668      PMCID： PMC7286383          DOI： 10.1093/cid/ciz735

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  16 in total

Review 1.  A Rationale for Change: An Increase in Invasive Pneumococcal Disease in Fully Vaccinated Children.

Authors:  Christopher C Blyth; Sanjay Jayasinghe; Ross M Andrews
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

2.  Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.

Authors:  Sanjay Jayasinghe; Rob Menzies; Clayton Chiu; Cindy Toms; Christopher C Blyth; Vicki Krause; Peter McIntyre
Journal:  Clin Infect Dis       Date:  2016-10-21       Impact factor: 9.079

3.  Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs?

Authors:  Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

Review 4.  Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Authors:  Andrew D Wiese; Marie R Griffin; Carlos G Grijalva
Journal:  Expert Rev Vaccines       Date:  2019-03-20       Impact factor: 5.217

5.  Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

Authors:  Pauline A Waight; Nicholas J Andrews; Shamez N Ladhani; Carmen L Sheppard; Mary P E Slack; Elizabeth Miller
Journal:  Lancet Infect Dis       Date:  2015-03-20       Impact factor: 25.071

Review 6.  Making sense of differences in pneumococcal serotype replacement.

Authors:  Joseph A Lewnard; William P Hanage
Journal:  Lancet Infect Dis       Date:  2019-01-29       Impact factor: 25.071

Review 7.  Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers.

Authors:  Cynthia G Whitney; David Goldblatt; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

8.  Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.

Authors:  David Goldblatt; Jo Southern; Nick J Andrews; Polly Burbidge; Jo Partington; Lucy Roalfe; Marta Valente Pinto; Vasilli Thalasselis; Emma Plested; Hayley Richardson; Matthew D Snape; Elizabeth Miller
Journal:  Lancet Infect Dis       Date:  2017-11-22       Impact factor: 25.071

Review 9.  Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis.

Authors:  Tinevimbo Shiri; Samik Datta; Jason Madan; Alexander Tsertsvadze; Pamela Royle; Matt J Keeling; Noel D McCarthy; Stavros Petrou
Journal:  Lancet Glob Health       Date:  2017-01       Impact factor: 26.763

10.  Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control.

Authors:  Dominic Thorrington; Nick Andrews; Julia Stowe; Elizabeth Miller; Albert Jan van Hoek
Journal:  BMC Med       Date:  2018-02-08       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.